To assess the prevalence and clinical impact of reductions in the skeletal muscle mass of patients with chronic heart failure (HF). Chronic HF is accompanied by co-morbidities that influence the quality of life and outcomes.
Introduction
Muscles undergo permanent changes. After age 50, the muscle mass declines by 1 -2% annually 1 and the muscle strength decreases by 1.5%. 2 This age-related muscle loss, termed sarcopenia, 3, 4 affects 10% of elderly subjects aged 60-70 years. After the age of 80, up to 50% of people can be affected. 5 Muscle wasting is not only a problem in the elderly, but also a consequence of chronic diseases. Pathophysiological processes can cause changes in metabolism and may consequently yield increased catabolism. 6 A discussion is currently ongoing whether or not the use of the term sarcopenia should be restricted to 'healthy ageing' and whether another descriptive term may be more appropriate in the setting of elderly patients with chronic disease. 7 In this sense, muscle wasting reflects sarcopenia in chronic disease. The prevalence and the impact of muscle wasting in heart failure (HF) have not been investigated yet. Chronic HF affects up to 14 million people in Europe alone. 8 The prognosis of chronic HF is poor and comparable with some types of cancer. 9 Half of the patients die within 4 years of diagnosis. 8 Chronic HF is often accompanied by co-morbidities, such as anaemia, chronic kidney disease, diabetes mellitus, or cachexia. 10, 11 All these co-morbidities have been shown to be associated with decreased exercise capacity and with functional impairment in affected patients. 12 The connection between chronic HF and weight loss has already been established some years ago, but it has not been described whether changes in muscle strength and function occur and whether these changes impact on the patients' functional capability. 13 The Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF) is a prospective, multinational, observational project into the co-morbidities type 2 diabetes mellitus, cachexia, and obesity in patients with chronic HF. We hypothesized that muscle wasting is prevalent among patients with chronic HF and has a significant impact on the patients' clinical status and on parameters of functional capacity.
Methods

Study population
We prospectively enrolled 200 ambulatory patients with clinically stable chronic HF of ,3 months' duration who took part in the SICA-HF project. Recruitment for this project was commenced in March 2010, and we included all subjects from the Department of Cardiology, Charité Medical School, Campus Virchow-Klinikum, Berlin, Germany who were recruited until April 2012. All subjects provided written informed consent at enrolment, and the local ethics committee approved the protocol. The study is funded by the European Commission's 7th Framework programme (FP7/2007-2013) under grant agreement number 241558 and fulfils all principles of the Declaration of Helsinki.
The study protocol has been published previously. 10 In brief, patients were eligible if they fulfilled the following criteria: age .18 years, clinical signs, and symptoms of chronic HF with a left ventricular ejection fraction (LVEF) ≤40% (HF with reduced ejection fraction, HFrEF) or with an LVEF .40% and a left atrial dimension ≥4.0 cm [HF with preserved ejection fraction (HFpEF)]. Patients with previous heart transplantation, cardiac, or embolic events within 6 weeks prior to the baseline examination, and patients on haemodialysis or with known pregnancy were excluded. Before inclusion, patients were screened by transthoracic two-dimensional echocardiography to assess the LVEF and other cardiac parameters. Blood was drawn early in the morning after an overnight fast and at least 15 min of supine rest to analyse the full blood count and routine clinical biochemistry parameters.
Assessment of muscle strength, muscle function, and functional capacity
All patients underwent a standardized protocol of different examinations of the muscle mass, muscle strength, and muscle performance. Dual energy X-ray absorptiometry (DEXA) was used to evaluate body composition. The DEXA scan measures total mass, lean, and fat mass. The lean mass has been used to estimate the muscle mass in our patients as previously described. 14 The appendicular lean mass was defined as the lean mass of both arms and legs combined. A scanner model 'lunar prodigy' and 'lunar en Core 2002' software were used to analyse the data (both from GE Medical Systems, Madison, WI, USA). The knee extension strength was assessed using an isokinetic dynamometer (Multitrace 2, Lectromed, Jersey, Channel Islands). The maximal strength was measured in both legs in a sitting position with the patient's legs hanging freely, the ankle fixed by a pressure transducer. The best of three measurements was used. Arm strength was analysed using the handgrip dynamometer (Saehan Coporation Korea Hydraulic Hand Dynamometer, model SH5001). Likewise, the best of three measurements was used. All patients underwent treadmill performance testing according to the modified Bruce protocol. 15 The modified Naughton protocol was used in selected patients. 16 Ventilation gases, such as the oxygen uptake (VO 2 in mL), carbon dioxide production (VCO 2 in mL), absolute peak oxygen consumption (absolute peakVO 2 in mL/min), and anaerobic threshold, were recorded. A 6-min corridor walk test as well as a 4-m walking (4-m walk) test was performed according to standard protocols. Therefore, time was measured for the 4-m distance and gait speed was calculated.
Muscle wasting was defined according to previously published criteria suggested to diagnose sarcopenia. 17 Thus, using data from the previously published Rossetta study, 19 we defined muscle wasting as a muscle mass 2 SD below the mean of a healthy young reference group aged 18 -40 years.
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The lean mass data from the DEXA scan were evaluated and the muscle mass index of patients 20 was calculated. This index assesses the appendicular skeletal muscle mass (ASM in kg), calculated as the lean muscle mass of both arms and legs 21 divided by the height (in metre) squared.
Assessment of serum cytokines
Venous blood was collected from an antecubital vein. Serum samples were immediately centrifuged and stored at -808C until the final analysis. Serum levels of interleukin (IL) 1b, IL-6, and the tumour necrosis factor-a (TNF-a) were analysed using magnetic cytokine assays purchased from Bio-Rad Laboratories GmbH (Munich, Germany), the lower limits of detection being 0.1, 0.1, and 0.4 pg/mL, respectively.
Statistical analysis
Data are presented as mean + standard deviation (SD) or median with percentiles. For statistical analysis, StatView 5.0 (SAS Institute, Inc., Cary, USA) was used. Serum levels of IL-1b, IL-6, and TNF-a were non-normally distributed and, therefore, log-transformed to achieve a normal distribution. Analysis of variance (ANOVA), Student's unpaired t-test, Fisher's exact test, Pearson's simple regression, and logistic regression were used as appropriate. A two-tailed P-value ≤0.05 indicates statistical significance.
Results
We enrolled 200 patients with symptomatic, clinically stable chronic HF, 138 (69%) of whom presented with chronic HFrEF and the remaining with HFpEF. The study cohort consisted of 159 male (79.5%) and 41 female participants. The average age of all patients was 66.9 + 10.4 years and the mean LVEF was 38.9 + 13.5%. Most patients were in New York Heart Association (NYHA) classes II and III. Baseline characteristics of patients are summarized in Table 1 .
Patients were divided according to whether or not muscle wasting was present. A total of 39 patients (19.5%) met these criteria, and their lean mass was lower in all body compartments when compared with patients without muscle wasting (all P , 0.04, Table 2 ). Patients with muscle wasting were predominantly men and tended to be older than patients without muscle wasting (P ¼ 0.01, Table 1 ). Their HF was predominantly ischaemic in origin with a reduced LVEF. Patients with muscle wasting also presented with a lower fat mass in all body compartments when compared with those without evidence of muscle wasting (all P , 0.001, Table 2 ). Likewise, body weight and the body mass index (BMI) were lower in patients with muscle wasting than in those without (both P , 0.0001, Table 1 ). No difference was detected between the two groups with regard to patients' medication ( Table 3) .
Both handgrip strength and quadriceps strength were lower in patients with muscle wasting than in those without (both P , 0.05, Figure 1A and B). No difference was detected between patients with vs. those without muscle wasting in terms of their ratio of muscle strength over muscle mass, neither for arms nor legs (both P . 0.2). The time required to walk 4 m was higher in patients with muscle wasting than in those without (P ¼ 0.002, Figure 1C ) and also a significant difference was found with regard to gait speed (P ¼ 0.03). Similarly, the distance walked in 6 min (6-min walk test) was lower in patients with muscle wasting (P ¼ 0.005, Figure 1D ). Cardiac function was likewise affected in that patients' LVEF was lower when muscle wasting was present (P ¼ 0.05, Figure 2A The peak oxygen consumption and the exercise time as assessed using spiroergometry were lower in patients with muscle wasting than in those without (both P , 0.001, Figure 2B and C ). Similarly, the anaerobic threshold (9.6 + 2.7 vs. 12.1 + 3.7, P ¼ 0.004) and the ventilation/carbon dioxide slope (VE/ VCO 2 -slope, 41.6 + 11.3 vs. 33.2 + 7.3, P , 0.0001) were significantly different between the two groups.
Serum levels of IL-6 were significantly different between patients with vs. those without muscle loss (P ¼ 0.001, Table 1 ). This was not the case for IL-1b or TNF-a ( 
Correlation analyses
In patients without muscle wasting we detected significant relationships between the ASM mass and quadriceps strength (r ¼ 0.53, P , 0.0001), handgrip strength (r ¼ 0.66, P , 0.0001), and absolute peak VO 2 (r ¼ 0.57, P , 0.0001). The same was true in patients with muscle wasting ( Figure 3A-C) . Serum levels of IL-6 correlated with the distance walked during 6 min (r ¼ 20. 
Exercise capacity
Using univariable logistic regression, we found that age, sex, BMI, presence of overweight or obesity, NYHA class, haemoglobin, presence of anaemia, LVEF, distance walked in the 6-min walk test, lean mass, presence of muscle wasting, and presence of coronary artery disease were all associated with reduced exercise capacity as assessed by spiroergometry, defined as exercise capacity below the median of the overall population (all P , 0.05, Table 4 ). Serum creatinine was not significantly correlated with reduced exercise capacity. The presence of muscle wasting remained independently associated with reduced exercise capacity after adjustment for age, sex, NYHA class, haemoglobin, LVEF, distance walked in 6 min, and the number of co-morbidities (odds ratio 6.53, 95% confidence interval 1.56-27.37, P ¼ 0.01, Table 4 ).
Discussion
This is the first study to evaluate the prevalence and clinical impact of muscle wasting in patients with chronic HF. A total of 19.5% of patients in this mixed cohort with clinically relevant HF presented with clinical features diagnostic of muscle wasting, defined using the criteria suggested to diagnose sarcopenia. These patients exhibit reduced exercise capacity as evidenced by significantly lower muscle strength in both the legs and the arms, reduced LVEF, and worse exercise capacity in treadmill performance as well as in the 6-min corridor and 4-m walk test. One of the key clinical features of HF is the reduction in exercise capacity that limits patients' activities of daily life. Such reduction in exercise capacity can be clinically assessed using the peak VO 2 or exercise time assessment and by the measurement of walking distance in the 6-min walk test. Reduced exercise capacity impacts on the patients' quality of life and prognosis. Preserving muscle mass and function can be viewed as pivotal to the maintenance of exercise capacity and, thus, quality of life.
It is interesting to note that the muscle mass is lost in chronic disease much earlier than, for example, fat tissue. 22 Weight loss has been identified as a major player in unfavourably influencing the prognosis in patients with chronic HF. 13 The types of tissue that cause weight loss have not been identified so far. The decline of muscle mass and muscle strength is part of the pathophysiology of the ageing process. Indeed, the structure of muscles changes in healthy ageing. For example, the character of muscle fibres switches from that of fast type 2 to slow type 1 fibres, and the muscle mass is replaced by adipose tissue. 23 All these changes lead to a decrease in muscle quality. According to data obtained in healthy adults aged 60-70 years, 5-13% are affected by pathologically important muscle wasting. 4 In our study, 19.5% are affected by muscle wasting, thus, considering the mean age of our patients, many more subjects than expected for ageing alone. One can assume that this chronic process is partly responsible for the greater loss of muscle mass. The fact that no difference was detected between patients with vs. those without muscle loss in terms of the ratio of muscle strength over muscle mass argues that the strength of the individual muscle unit is not altered. In general, sarcopenic elderly subjects display several features that may contribute to reduced functional capacity and disability, 24 and an increase in hospitalization and healthcare costs. 25 The latter two are particularly influenced by a higher risk of falls. 26 In addition, sarcopenic elderly subjects display an increased mortality rate. 27, 28 Previous studies have highlighted the presence of muscle wasting in subjects with chronic illnesses other than chronic HF. The Third National Health and Nutrition Examination Survey (NHANES III) study, for example, revealed the relation between impaired kidney function and an increase in the prevalence of muscle wasting. 29 Muscle wasting is also common among patients with chronic obstructive pulmonary disease. 30, 31 Furthermore, the Korean Sarcopenic Obesity Study (KSOS) detected sarcopenia/ muscle loss in patients with type 2 diabetes mellitus 32 as well as in patients with liver cirrhosis evaluated for liver transplantation. 33 The pathophysiology of muscle wasting in elderly healthy subjects or in patients with chronic illnesses is less clear. It is suspected that inflammatory processes may lead to metabolic changes. These changes lead to a imbalance between anabolic and catabolic signals. 34 This stimulation of catabolic pathways directly affects the skeletal muscle and induces protein breakdown. 35 Pro-inflammatory cytokines, like IL-6 and TNF-a, intensify catabolism. 36 High levels of these inflammatory mediators activate the ubiquitine-proteasome pathway that degrades proteins. 32 This is one of the pathways potentially involved in muscle wasting. Indeed, patients with chronic illnesses often present with a highserum level of these pro-inflammatory cytokines, 32,37 and we also detected significantly elevated serum levels of IL-6 in our cohort of patients. The mechanisms of muscle wasting and cachexia may be overlapping to some degree. Indeed, patients with muscle wasting may also display features of cachexia. The presence of cachexia implies a loss of body weight, usually defined as a loss of 5% of body weight within 6 months or less in the presence of chronic illness. 38 However, the term cachexia does not imply the loss of a particular type of tissue, and the tissues involved may embrace muscle, fat tissue, or bone. 39 Patients with muscle wasting, on the other hand, lose functional tissue, and the degree of muscle wasting may or may not lead to the development of cachexia as well. Cachexia, in turn, may or may not be associated with functional impairment, although one would usually expect a loss of exercise capacity in these patients as well. With regard to developing novel therapeutic approaches, it may be important to differentiate the two distinct clinical phenomena, because patients may in clinical practice present with muscle wasting only, with cachexia only, or with both at the same time. Patients with either diagnosis may benefit from tailored therapies that emphasize gaining muscle or body weight. Physical fitness and exercise training have a great impact in preventing the loss of muscle mass. 40 Other arrangements, such as nutritional supplementation of amino acids, 41 hormone substitution, especially testosterone, 42 or vitamin D replacements, 43 are other therapeutic options in affected patients. These possibilities are currently limited to patients outside clinical routine, for example, in patients with terminal disease, as evidence from randomized trials is scarce and no guidance has been implemented in the treatment guidelines. Some limitations, however, should be considered when looking at our data. We did not include a prospectively recruited group of control subjects but rather analysed data from a historical reference group. In addition, the inclusion criteria of SICA-HF are broad. Although we are confident that our data can thus be extrapolated to many patients with clinical signs of HF, it is not clear whether our data can be reproduced in, for example, patients with HFpEF using stricter criteria such as the ones suggested by the European Society of Cardiology. 8 Finally,
we did not differentiate patients with and without cachexia at study entry. Muscle wasting is a process that is restricted to the muscle and it does not usually cause weight loss. Thus, patients may present with muscle wasting alone or in combination with cachexia. Future studies need to consider this point.
In conclusion, this single-centre experience from the multinational SICA-HF study shows that muscle wasting is a frequent comorbidity among patients with chronic HF. Compared with patients without muscle wasting, patients affected by muscle wasting have lower muscle strength, worse exercise capacity in treadmill performance and in walking exercise tests, and reduced LVEF. Larger studies are required to pave the way for developing tailored therapies for this important subgroup of patients.
